Fatigue After Breast Cancer Treatment Linked to Depression and Stress, suggests study
Researchers have found in a cohort of patients with breast cancer that clinically significant fatigue developed or increased in 34% of patients within 2 years of starting treatment. The association was partly mediated by depressive symptoms and perceived stress, independent of cardiovascular risk factors, age, and changes in left ventricular ejection fraction or strain.
Patients with breast cancer (BC) may have long-term fatigue after treatment, which is associated with reduced quality of life.
A study was done to identify cardiac, psychological, and cancer treatment factors associated with fatigue before and 24 months after BC treatment. This cohort study was conducted across multiple community hospital-based cancer centers among participants with stage I to III BC receiving potentially cardiotoxic chemotherapy or aromatase inhibitors and noncancer comparators.
Participants were enrolled from May 2017 to July 2021 and followed up for 24 months. Data were analyzed between July 2023 and July 2026. It was hypothesized that chemotherapy-associated changes in left ventricular function were associated with and mediated 2-year post-BC treatment fatigue. Outcome measures included fatigue, sociodemographic variables, hematocrit, left ventricular ejection fraction and circumferential strain, cardiovascular comorbidities, 6-minute walk distance, perceived stress, and depressive symptoms.
From a total of 381 patients, patients with BC (236) and noncancer comparators (145) had a mean (SD) age of 54 (12) years. Two years after BC treatment, 33 (18.2%) receiving potentially cardiotoxic chemotherapy experienced clinically relevant fatigue (χ2 test P < .001 relative to aromatase inhibitors or controls), and 62 (34.6%) experienced a significant increase in fatigue relative to their precancer treatment fatigue level (χ2 test P < .001, relative to aromatase inhibitors and controls).
Independent of pretreatment and posttreatment left ventricular ejection fraction, diabetes status, hypertension, tobacco use, age, body mass index, hematocrit, receipt of potentially cardioprotective medications, and chemotherapy regimens, only depressive symptoms (estimate, −0.77; 95% CI, −0.83 to −0.71; P < .001) and perceived stress (−0.32; 95% CI, −0.41 to −0.24; P < .001) were associated with and mediated 24-month post-BC treatment fatigue measures. Baseline adjusted changes in 6-minute walk distance, left ventricular ejection fraction, and left ventricular strain were not associated with 24-month post-BC treatment fatigue levels.
In this cohort study of patients with BC, clinically relevant fatigue increased in 34% of patients 2 years after initiating cancer treatment mediated partly by depressive symptoms and perceived stress regardless of cardiovascular risk factors, age, or change in left ventricular ejection fraction and/or strain.
Reference:
Avis NE, O’Connell NS, Mihalko SL, et al. Long-Term Fatigue After Treatment for Breast Cancer. JAMA Netw Open. 2026;9(8):e2629862. doi:10.1001/jamanetworkopen.2026.29862
